Thursday, March 23, 2017 3:34:19 AM
Thanks for your answer. It is hard to know what is going to happen.
I guess about Mac, well first they say no, and them they say yes. It doesn't really make any sense not to reach the endpoint and then go for it. I guess the most positive they can get is a new trial to confirm data. I guess that is why the share price is dropping. If you want to go for Zoptrex you might be better off after the meeting with the FDA because most likely it will be thumps down.
I guess the companies behavior only adds to the lack of confidence and send DD in the shades.
I don't understand your point about the 50 million. Isn't it ATM which gives the company the right to sell new shares up to the total amount of 50 million? Well, if they fail or have to do new trials they can raise the money through ATM, but it might be at a price of 1 dollar or even less. The new shares then add to the 13,5 mill shares.
For me the strongest point is that they have made partnership not with one , but as far as I remember, with four companies including China's biggest Sinopharm A-think. I guess they all have made heavy research before making partnership all though it has been a cheap deal with no upfront payment except for A-think. But they all have to make the effort and spend money, and I guess a quick way for Aezs to get Zoptrex to the marked in different parts of the world.
But if Zoptrex works, the sky is not the limit. The pipeline alone is worth tremendous and I guess the company will be a buyout target and we will be sitting on mars.
All the best and behavour like an insisting virgin! ( Danish joke)
Recent CSCI News
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 09/06/2024 06:04:41 PM
- COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 08/27/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:17 PM
- COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM